Rating Change
Morgan Stanley analysts reiterated a Equal-Weight rating on Amgen Inc. (NASDAQ:AMGN) on July 08, 2026.
reiterateNASDAQ:AMGN
Morgan Stanley Reiterates Equal-Weight Rating on Amgen Inc. (AMGN)
Rating Change Morgan Stanley analysts reiterated a Equal-Weight rating on Amgen Inc. (NASDAQ:AMGN) on July 08, 2026. Market Context Amgen Inc.
Market Context
Amgen Inc. operates in the Healthcare sector. The stock currently trades at $367.99 with a market capitalization of $209.2B. The stock has gained 16.6% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amgen Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amgen Inc.
Among the 10 most recent ratings: 2 Buy, 8 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Jul 07, 2026 | Truist Securities | Hold | N/A |
| Jul 06, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Jun 16, 2026 | Mizuho | Neutral | N/A |
| Jun 10, 2026 | Morgan Stanley | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View AMGN Stock Page
Frequently Asked Questions
What does a Equal-Weight rating mean for AMGN?
A Equal-Weight rating from Morgan Stanley reflects the analyst's outlook on Amgen Inc. (NASDAQ:AMGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMGN forecast page.